Literature DB >> 20008612

Chronic myeloid leukemia: reversing the chronic phase.

John M Goldman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008612     DOI: 10.1200/JCO.2009.26.5587

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Authors:  F J Giles; E Abruzzese; G Rosti; D-W Kim; R Bhatia; A Bosly; S Goldberg; G L S Kam; M Jagasia; W Mendrek; T Fischer; T Facon; U Dünzinger; D Marin; M C Mueller; Y Shou; N J Gallagher; R A Larson; F-X Mahon; M Baccarani; J Cortes; H M Kantarjian
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.